The treatment groups were well matched demographically ( Table I). A total of 270 patients (of 774 recruited) were randomized as follows: rosuvastatin monotherapy (n=46), ER niacin monotherapy (n=72), ...

WILMINGTON, Del.--(BUSINESS WIRE)-- AstraZeneca (NYSE: AZN) today announced results of the LUNAR (Limiting UNdertreatment of Lipids in Acute Coronary Syndrome with Rosuvastatin) study, which showed ...

AstraZeneca today announced the launch of a new clinical trial, SATURN, designed to measure the impact of CRESTOR™ (rosuvastatin) 40 mg and atorvastatin (Lipitor®) 80 mg on the progression of ...

Crestor rosuvastatin calcium is a statin drug, that works by slowing the production of cholesterol by the body, used to lower cholesterol and fats triglycerides in the blood and is used to reduce the ...

Kyoto, Japan, Monday 29 September 2003. New data presented at the XIIIth International Symposium on Atherosclerosis (ISA) show AstraZeneca's highly effective statin CRESTOR (rosuvastatin) achieves ...

Government of Newfoundland and Labrador. Strength This refers to the amount of the active medicinal ingredient e. Benefit Status Open - Drugs which are reimbursed with no criteria or prior approval.

Rome, Italy - New data from the Comparative Effects on Lipid Levels (COMPELL) trial, presented here at the International Symposium on Atherosclerosis, provide further support for the addition of ...

SAN FRANCISCO, CA—Statin-naïve patients with non-ST-segment elevation acute coronary syndrome (NSTE-ACS) scheduled for early invasive procedures who receive high-dose rosuvastatin on admission have a ...

A 76-year-old Filipina woman who had been taking rosuvastatin 40 mg per day without a problem for more than 5 years started developing pain and weakness in her thighs just days after starting on the ...

LONDON, January 15 /PRNewswire/ -- AstraZeneca (LSE: AZN) (NYSE: AZN) today announced the launch of a new clinical trial, SATURN, designed to measure the impact of CRESTOR(TM) (rosuvastatin) 40 mg and ...